We believe that the pharmacological activation of CYP46A1 could compensate for NPC1 deficiency and correct synaptic changes, therefore compensating cognitive and psychiatric alterations in patients with NPC. The gene discussed is NPC1; the disease is nasopharyngeal carcinoma.